Australia's Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Australia's Therapeutic Goods Administration rescheduled psilocybin and MDMA in 2023, enabling psychedelic-assisted psychotherapy (PAP) through an Authorised Prescriber pathway for treatment-resistant depression and PTSD. Early rollout was slow: fewer than 100 patients accessed PAP in the first 18 months. Uptake grew in 2025 as referral pathways formed and as the safety picture clarified, including aggregated TGA data through September 2025 reporting zero serious adverse events in 87 MDMA patients and 47 psilocybin patients. Scaling in 2026 hinges on workforce capacity, protocol reviews, and maintaining safety thresholds. The article highlights reimbursement progress via Medibank and Veterans' Affairs funding, plus the role of the AIPPAP-RR registry and the push for culturally responsive practice, including Indigenous therapist inclusion and cultural training. It also notes potential future shifts if broader eligibility expands (for example, end-of-life distress) and how future FDA-style approvals might affect Australia's psychotherapy-centered model.